US 11952364
TRK inhibitors useful as anticancer drugs
granted A61KA61K31/4439A61K45/06
Quick answer
US patent 11952364 (TRK inhibitors useful as anticancer drugs) held by TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED
- Grant date
- Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K31/4439, A61K45/06, A61P, A61P35/00